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Abstract 
The GAP multidisciplinary study carried out in South London, recruited 410 first 
episode of psychosis patients and 370 controls; the aim was to elucidate the multiple 
genetic and environmental factors influencing the onset and outcome of psychosis.  
The study demonstrated the risk increasing effect of adversity in childhood (especially 
parental loss, abuse, and bullying) on onset of psychosis especially positive symptoms.  
Adverse life events more proximal to onset, being from an ethnic minority, and 
cannabis use also played important roles; indeed, one quarter of new cases of 
psychosis could be attributed to use of high potency cannabis. The "jumping to 
conclusions" bias appeared to mediate the effect of lower IQ on vulnerability to 
psychosis. 
We confirmed that environmental factors operate on the background of polygenic 
risk, and that genetic and environment act together to push individuals over the 
threshold for manifesting the clinical disorder. The study demonstrated how biological 
pathways involved in the stress response (HPA axis and immune system) provide 
important mechanisms linking social risk factors to the development of psychotic 
symptoms. Further evidence implicating an immune/inflammatory component to 
psychosis came from our finding of complement dysregulation in FEP. Patients also 
showed an upregulation of the antimicrobial alpha-defensins, as well as differences in 
expression patterns of genes involved in NF-κB signaling and Cytokine Production. 
Being of African origin not only increased risk of onset but also of a more difficult 
course of illness. The malign effect of childhood adversity predicted a poorer outcome 
as did continued use of high potency cannabis.   
 
  
Introduction 
South London has been the focus of a series of investigations of psychosis, of which 
the best known are the Camberwell incidence studies of schizophrenia between 1964 
and 1997 (Castle et al., 1998; Boydell et al., 2003), and the Aetiology and Ethnicity in 
Schizophrenia and Other Psychoses (AESOP) incidence and outcome studies (Fearon 
et al., 2006; Morgan et al., 2014a, 2014b). Sequential data from 1964 showed a 
steadily increasing incidence of psychosis, thought to be due to the excess in migrants, 
and to the increase in cannabis use (Castle et al., 1998; Boydell et al., 2006). The AESOP 
study demonstrated a higher incidence of psychosis in South London than in Bristol 
and Nottingham (Kirkbride et al., 2006); derivative studies using similar methodology 
also showed lower incidence rates in Sao Paulo, Brazil (Menezes et al., 2007) and 
Palermo, Sicily (Mulè et al., 2017).  
However, few data of a biological nature were collected in the above studies, and 
limited information on recreational drug use.  Therefore, we initiated a new case-
control study of first episode psychosis (FEP) to include the collection of samples for 
genome-wide association studies (GWAS), and which was, therefore, termed the 
Genetics and Psychosis (GAP) study. As well as repeating the psychological and social 
measures from AESOP and collecting information concerning drug use, we examined 
the hypothalamic pituitary adrenal (HPA) axis and immune response.  Thus, the study 
set out to combine biological, social and drug data into an integrated model of the 
onset and outcome of psychosis. 
The GAP study baseline data collection ran from 2005 till 2010, and thereafter the 
sample has been followed up until the present; over 37 reports have been published. 
This paper summarizes the important findings and highlights directions for future 
research.  
Methods 
Patients: We approached all patients aged 18–65 years who presented to the South 
London and Maudsley (SLaM) NHS Foundation Trust, with FEP. Patients were invited 
to participate if they met the International Classification of Diseases (ICD)-10 criteria 
for a diagnosis of non-affective (F20–F29) or affective (F30–F33) psychosis (World 
Health Organization, 1992a). Clinical data were collected using the Schedules for 
Clinical Assessment in Neuropsychiatry (SCAN) (World Health Organization, 1992b). 
ICD-10 diagnoses were determined using the OPCRIT checklist (McGuffin et al., 1991). 
We recruited healthy controls who were representative of the local population.  A 
total of 410 FEP patients, and 370 controls agreed to participate.  Further details of 
the methods can be found in Di Forti et al (Di Forti et al., 2009, 2014) and in the papers 
cited below. 
 
Social Adversity 
One of the clearest findings was the important role that social adversity plays in 
psychosis. Compared with controls, FEP patients were three times more likely to have 
experienced parental loss, and twice as likely to report a long-term separation from a 
parent in childhood. Parental separation, sexual and physical abuse were specifically 
associated with the ‘positive’ psychosis dimension, thus confirming previous reports 
(Ajnakina et al., 2016).  
More patients reported having been victims of bullying than community controls 
(Trotta et al., 2013). Interestingly, there was an association between bullying 
victimization and psychosis-like experiences amongst controls, suggesting an 
aetiological continuum underlying psychotic phenomena both in the general 
population and in the clinic.  
Patients were also more likely to show two or more markers of social disadvantage in 
adulthood (living alone, being single, unemployed), not only at first contact with 
psychiatric services but also up to 5 years prior to first contact (Stilo et al., 2013, 2017), 
with evidence of cumulative effect. Patients had also experienced more stressful life 
events close to psychosis onset, and subjectively felt more stressed than healthy 
controls (Mondelli et al., 2010a). Childhood adversities were associated with 
subsequent cannabis use (Sideli et al., 2015) but not with cognitive functioning (Sideli 
et al., 2014). 
 Hypothalamic-Pituitary-Adrenal axis and Immune markers of stress 
In order to understand the mechanisms linking social adversity to psychosis, we 
investigated the hypothalamic-pituitary-adrenal (HPA) axis and the peripheral 
immune system. FEP patients with less than two weeks of antipsychotic treatment 
had higher diurnal cortisol levels than healthy controls. The difference was not present 
in patients with longer duration of antipsychotic treatment, implying that 
antipsychotics may normalize raised cortisol levels.  
The cortisol awakening response, a marker of how the HPA axis reacts to stress, was 
blunted in patients (Mondelli et al., 2010a); this was unrelated to antipsychotics.  
There was a divergent effect of childhood abuse on the HPA axis in FEP and controls. 
Following exposure to such abuse, a blunted cortisol awakening response and less 
reactive HPA axis may represent one of the biological pathways to psychosis (Ciufolini 
et al., 2019). This low cortisol awakening response was associated with worse 
cognitive functioning, in particular a more severe deficit in verbal memory and 
processing speed (Aas et al., 2011). 
FEP patients showed increased serum levels of inflammatory markers such as tumor-
necrosis-factor (TNF)-alpha and interleukin (IL)-1alpha (Di Nicola et al., 2013); TNF-
alpha levels were particularly high in those patients with a history of childhood trauma 
suggesting early traumatic experience can facilitate increased adulthood 
inflammation. Another inflammatory marker, C reactive protein (Hepgul et al., 2012), 
showed higher serum levels in patients with experience of childhood sexual abuse 
than both healthy controls and patients without childhood sexual abuse.  Further 
evidence implicating an immune/inflammatory component to psychosis came from 
our finding of compliment dysregulation in FEP (Kopczynska et al., 2019); complement 
is, of course, a key driver of inflammation. 
Interestingly, increased levels of the pro-inflammatory cytokine IL-6, as well as low 
levels of the neurotrophic factor BDNF, were associated with smaller left hippocampal 
volume (Mondelli et al., 2011). High levels of cortisol during the day were also 
associated with smaller left hippocampal volumes (Mondelli et al., 2010b). Indeed, 
diurnal cortisol, IL-6 and BDNF all independently affected hippocampal volume in FEP 
(Mondelli et al., 2011). Thus, the excessive HPA and immune responses to stress 
around the onset of psychosis may contribute to the decrease in hippocampal volume 
observed over this period. 
 
Cannabis use 
It is now well established that cannabis use can increase the risk of psychosis (Murray 
et al., 2013; Di Forti et al., 2015), although the mechanism remains unclear (Luizi et al, 
2008; Murray et al, 2016). The GAP study was the first to show the importance of the 
pattern of cannabis use (Di Forti et al., 2009), and that people who used a type of 
cannabis with high concentration of Delta-9-Tetrahydrocannabinol (THC) were at 
almost 3 times greater risk of suffering from a psychotic disorder, rising to over 5 
times, if they used it daily, compared with those who never used; they also 
experienced psychosis onset on average 6 years earlier than never users (Di Forti et 
al., 2014). 
The association between use of high potency cannabis and risk of psychosis was not 
explained by differences in socio-demographic characteristics, other drug use, or 
genetic load for psychosis (Di Forti et al., 2015). Indeed, we calculated that in South 
London, the proportion of first- episode psychosis attributable to use of high potency 
cannabis was 24% (Di Forti et al., 2015).  
 A number of studies have reported better cognitive performance in those patients 
with psychosis who used cannabis, compared with those who had not. This is 
surprising as cannabis can impair cognition in healthy subjects. The GAP study offered 
a possible explanation by showing that FEP patients who had smoked cannabis had 
not only a higher current IQ but also a higher premorbid IQ than patients who had 
never used cannabis (Ferraro  et al., 2013); this difference was not found among 
controls; cannabis appears to play a role in provoking psychosis in people who were 
less neurodevelopmentally impaired than is generally the case in psychosis. One 
possible mechanism for this could be the disturbed microstructural organization of 
the corpus callosum which we found associated with use of high potency cannabis 
(Rigucci et al., 2016). 
An analysis of reasons for use of cannabis found little evidence in support of a 'self-
medication’ motive (Kolliakou et al., 2015).  Interestingly, FEPs were more likely to 
report both ‘bad’ (i.e. exacerbation of psychotic like experiences) and ‘enjoyable’ (i.e. 
feeling high, full of ideas) experiences than controls when using high-potency cannabis 
(Bianconi  et al., 2016). In this way, greater pleasurable effects of cannabis may 
reinforce its continued use in those who become psychotic, despite the concomitant 
exacerbation of psychotic symptoms. 
Candidate genes 
We replicated a report of an interaction between the AKT1 (rs2494732) genotype and 
cannabis use (Di Forti et al., 2012) in conveying vulnerability to psychosis; similarly we 
found evidence of interaction between cannabis use and variation at the DRD2 gene 
(Colizzi et al., 2015). These findings that individual genes may influence susceptibility 
to cannabis-induced psychosis must remain tentative till further confirmed. There was 
no evidence of interaction between COMT Val158Met, AKT1, or DRD2 polymorphisms 
and exposure to childhood adversity in relation to psychosis onset (Trotta et al., 2018). 
 
Whole-genome approaches 
We calculated the polygenic risk score for schizophrenia (PRS-Sz), which summarises 
genome-wide data into a single variable that measures genetic liability to the disorder 
(Vassos et al., 2017). We found PRS-Sz to be a powerful predictor of case-control 
status in European individuals (9.4% of the variance explained), but not in individuals 
of African ancestry. Interestingly, PRS distinguished cases who acquired a 
schizophrenia diagnosis from those with other psychotic disorders such as delusional 
disorder, affective psychosis or brief psychotic episode. This was the first study to 
demonstrate the potential clinical utility of PRS, and included a replication in a sample 
of patients with chronic schizophrenia. 
We then examined the interplay between PRS and childhood adversity in FEP but did 
not find evidence of interaction (Trotta et al., 2016a). We also examined the interplay 
of childhood adversity and familial risk, using family history as a proxy of the overall 
genetic loading to psychosis (Trotta et al., 2015). Again we found no interaction 
between the two risk factors.  We concluded that genetic liability whether measured 
by family history or molecular means, and childhood adversity contribute 
independently to the aetiology of psychosis. 
Gene Expression:    
When comparing the blood transcriptome of FEP patients and healthy controls, 
we found evidence for multiple disrupted pathways, primarily related to oxidative 
stress and immune signaling. We notably found an upregulation of the 
antimicrobial alpha-defensins in FEP patients, as well as differences in expression 
patterns of genes involved in NF-κB signaling and Cytokine Production. (Leirer et al., 
2019). These effects could not be explained by anti-psychotic medication, and in 
fact medication correlated with a reduction in the magnitude of changes between 
FEP patients and controls. 
Psychological Mechanisms 
We focused on the “jumping to conclusions” (JTC) data-gathering bias.  Half of the 
FEPs jumped to conclusions on at least one of tasks proposed, compared with 25% of 
controls (Falcone et al., 2015a). JTC was associated with severity of clinical delusions, 
and with worse neuropsychological functioning in both cases and controls. Each point 
decrease in IQ increased the likelihood of JTC by around 4%. This finding suggests that 
JTC operates to mediate the effect of lower IQ on vulnerability to psychosis.  
All those with persisting delusions at 12 months jumped to conclusions either at 
baseline or follow-up, compared to half of those with no, or amenable, delusions 
(Falcone et al., 2015b). Over the 4 years following onset, JTC predicted longer 
admissions, more compulsory admissions and police involvement (Rodriguez et al., 
2018). 
 
Outcome 
Biological markers: Both a blunted cortisol awakening response and increased levels 
of inflammatory markers, such as IL-6 and interferon (IFN)-gamma, at baseline 
predicted poor response at three months (Mondelli et al., 2015) . Worse metabolic 
and inflammatory status onset, characterized by high C reactive protein, high body 
mass index and high triglycerides levels, predicted poor treatment response at 1-year 
follow-up (Nettis et al., 2019). 
MRI examination also showed that poor treatment response three months after onset 
was predicted by abnormal gyrification (Palaniyappan et al., 2013) and decreased 
white matter integrity (Marques et al., 2014). 
Risk Factors: Black patients had longer inpatient stays, higher rates of compulsory 
admissions and increased instances of police involvement during re-admission 
compared with patients of White British ethnicity during the first 5 years of illness 
(Ajnakina et al, 2017).  
Childhood physical abuse was associated with almost 3-fold increased odds of not 
being in a relationship at 1-year follow-up compared to non-abused patients (Trotta 
et al, 2016b). Greater service utilisation over 5 years (Ajnakina et al, 2018) was 
predicted by institutional care and by death of a biological parent;  parental separation 
was associated with non-compliance with medication. 
Lack of insight at baseline predicted symptom severity at long-term follow-up 
(O’Connor et al., 2013, 2017). Previous suicide attempts, and depression both of which 
were linked with baseline insight levels, predicted subsequent suicidal behavior 
(Lopez-Morinigo et al., 2019). 
Cannabis use: Those who stopped using cannabis had the most favourable course of 
illness (Colizzi et al., 2016; Schoeler et al., 2016a). In contrast, those who continued 
using high-potency cannabis daily showed fewer months until a relapse occurred, 
more relapses, and required more intensive psychiatric care (Schoeler et al., 2016a, 
2016b, 2017a, 2017b). Continued use of cannabis was also associated with poorer 
adherence to prescribed antipsychotic medications but this link did not fully explain 
the adverse long-term outcomes seen in cannabis-using FEPs (Colizzi et al., 2016; 
Schoeler et al., 2016a, 2016b, 2017a, 2017b). 
Treatment Resistance: Five years after onset, one third of patients who initially 
received a diagnosis of schizophrenia met criteria for Treatment Resistance. 70% of 
such patients did not respond to an antipsychotic from their first contact with mental 
health services for psychosis (Lally et al., 2016), which fits with the idea that there may 
be a distinctive poor outcome subgroup which shows no striatal dopaminergic excess 
(Demjaha et al., 2012). A study using the ten-year outcome data from the AESOP 
similarly reported two types of treatment resistance (Demjaha et al., 2017). This and 
the evidence noted above that abnormal gyrification and white matter integrity are 
associated with poor treatment response, raises the question of whether this is a 
neurodevelopmentally damaged group. The other 30% of the treatment resistant 
patients initially responded to antipsychotics, before becoming resistant, suggesting 
that the loss of response in these cases could be due to the emergence of dopamine 
receptor supersensitivity (Murray et al., 2016). 
Conclusions 
The GAP study demonstrated the influence of number of different risk factors on the 
onset of psychosis. It further clarified the effect of adversity in childhood (especially 
parental loss, abuse, and bullying) reported in the AESOP study, and associated it  
particularly with development of positive psychotic symptoms. As in the Camberwell 
Functional Psychosis Study  (Bebbington et al, 1993), we found that adverse life events 
proximal to onset increased risk.  And as in all our previous studies in South London, 
being from an ethnic minority especially of African ancestry, also played an important 
role. In addition, about one quarter of new cases of psychosis could be attributed to 
daily use of high potency cannabis.  A subsequent study carried out by Di Forti et al 
(2019) showed that this proportion had risen to 30%, possibly due to the further 
increase in the potency of the available cannabis.  
Biological pathways involved in the stress response (HPA axis and immune system) 
provide important mechanisms linking risk factors to the development of psychotic 
symptoms The GAP study confirms that environmental factors operate on the 
background of polygenic risk for schizophrenia but our preliminary evidence does not 
show gene-environment interaction; for example, genetic loading and childhood 
adversity appeared to act in a simple additive manner to propel the individual over 
the threshold for manifestation of psychosis.   
It is not surprising that risk factors for onset such as adversity, ethnicity, and cannabis 
use also played a role in determining the outcome. if an individual has suffered 
sufficient adversity to contribute to onset of psychosis, then one can understand how 
this malign effect can carry over to influence outcome. On the other hand, if the 
aetiological factor can be removed, e.g. by ceasing high potency cannabis use, then 
outcome can be much better.  The fact that black patients still have a worse outcome 
than their white counterparts should alarm British policy makers given the huge 
attention that this issue has received in the UK over more than two decades. 
Several of the biological findings in GAP have subsequently been confirmed.  Other 
studies have replicated the presence of a blunted cortisol awakening response in 
patients with first episode psychosis and schizophrenia, as also supported by a recent 
meta-analysis (Berger et al., 2016). Increased levels of inflammatory markers have 
been reported by subsequent studies in first episode psychosis (Zajkowska and 
Mondelli, 2014; Corsi-Zuelli et al 2019; Pillinger et al., 2019). To our knowledge, no 
subsequent study has yet been published investigating the association between such 
stress biomarkers and cognitive function or hippocampal volume specifically in first 
episode psychosis. 
The polygenic risk score for schizophrenia, although a useful measure of overall 
genetic loading, is perhaps too non-specific to elucidate interactions with individual 
environmental factors.  A larger study might enable examination of specific gene sets, 
for example, whether endocannabinoid genes influence susceptibility to cannabis-
induced psychosis, or whether genes influencing the striatal dopamine response 
render certain individuals exposed to childhood adversity especially prone to 
psychosis. 
The GAP study also exemplifies the limitations of FEP studies carried out in one 
location. Firstly, although we confirmed the main risk factors for psychosis which we 
had found in our previous studies in South London, it is likely that different risk factors 
for psychosis play a role of varying importance in different countries, depending, for 
example, on the extent of migration or the availability of high potency cannabis. 
Secondly, studies from one centre are likely to be too small to enable exploration of 
how risk factors co-occur or interact with each other. Similarly, although we found a 
number of predictors of poor outcome, the study did not have sufficient power to 
examine their joint effect.  
 
Implications for the future 
The last two decades have seen the elucidation of many of the contributing 
environmental causes of psychosis; the GAP study has contributed to this advance. 
However, it remains unclear if, and how, such environmental risk factors interact with 
each other or with susceptibility genes to cause the disorder, or whether their 
combined effect is just the sum of their individual effects. Furthermore, we know little 
of the pathogenic pathways linking risk factors to expression of disorder.  Larger 
multicenter first episode studies which span different countries and continents are 
now necessary. Such studies should include not only examination of genetic and 
biological pathways but also follow-up over a number of years. Such expensive studies 
which are common in medicine are now required in psychosis research.  
Now that we have some knowledge of individual risk factors for psychosis, then an 
obvious next step is to attempt to limit exposure to these factors. The findings 
concerning cannabis are of particular importance particularly because of the 
increasing availability in many countries of high potency cannabis. It is time to develop 
a public health strategy for the prevention of psychosis addressing potentially 
modifiable risk factors such as cannabis us. 
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